Immune-modulation by epidermal growth factor receptor inhibitors: implication on anti-tumor immunity in lung cancer
JS Im, AC Herrmann, C Bernatchez, C Haymaker… - PLoS …, 2016 - journals.plos.org
Skin toxicity is the most common toxicity caused by Epidermal Growth Factor Receptor
(EGFR) inhibitors, and has been associated with clinical efficacy. As EGFR inhibitors …
(EGFR) inhibitors, and has been associated with clinical efficacy. As EGFR inhibitors …
Current state and future directions of EGFR-directed therapy in head and neck cancer
P Tathineni, N Joshi, MJ Jelinek - Current Treatment Options in Oncology, 2023 - Springer
Opinion Statement Epidermal growth factor receptor (EGFR) is commonly overexpressed in
many head and neck squamous cell carcinomas (HNSCC). With the success of EGFR …
many head and neck squamous cell carcinomas (HNSCC). With the success of EGFR …
Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell …
Z Li, J Liao, Z Yang, EY Choi, RG Lapidus, X Liu… - British journal of …, 2019 - nature.com
Background Epidermal growth factor receptor (EGFR) plays an important role in head and
neck squamous cell carcinoma (HNSCC) proliferation and therapy resistance, but the …
neck squamous cell carcinoma (HNSCC) proliferation and therapy resistance, but the …
EGFR inhibition as a therapy for head and neck squamous cell carcinoma
J Loeffler-Ragg, I Schwentner, GM Sprinzl… - Expert opinion on …, 2008 - Taylor & Francis
Background: Improved understanding of disease biology of head and neck squamous cell
carcinoma (HNSCC) with nearly universal expression of EGFR has led to the introduction of …
carcinoma (HNSCC) with nearly universal expression of EGFR has led to the introduction of …
Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell …
KM Burcher, CH Bloomer, E Gavrila… - Therapeutic …, 2024 - journals.sagepub.com
Background: Immunotherapy with programmed death receptor-1 (PD-1) inhibitors, as a
single agent or in combination with chemotherapy, is the standard first-line treatment for …
single agent or in combination with chemotherapy, is the standard first-line treatment for …
Clinical development of molecular targeted therapy in head and neck squamous cell carcinoma
A better understanding of cancer biology has led to the development of molecular targeted
therapy, which has dramatically improved the outcome of some cancer patients, especially …
therapy, which has dramatically improved the outcome of some cancer patients, especially …
Exceptional response to cetuximab monotherapy in a patient with metastatic oropharyngeal squamous cell carcinoma: a molecular insight
P Peddi, B Paryani, A Takalkar, P Bundrick… - OncoTargets and …, 2016 - Taylor & Francis
Background Metastatic head and neck squamous cell carcinoma (HNSCC) carries a very
poor prognosis. A better understanding of the molecular driver of the disease and the …
poor prognosis. A better understanding of the molecular driver of the disease and the …
NKG2A immune checkpoint blockade potentiates cetuximab induced ADCC in head and neck cancer preclinical model
C Soulas, A Lalanne, C Bonnafous, C Hoffman… - Cancer Research, 2018 - AACR
Monalizumab (IPH2201) is a first-in-class humanized IgG4 targeting NKG2A (Natural Killer
Group 2A), which is expressed as a heterodimer with CD94 at the surface of subsets of NK …
Group 2A), which is expressed as a heterodimer with CD94 at the surface of subsets of NK …
Targeting HER3 and PI3K in head and neck squamous cancer cells.
Q Sheng, HQ Wang, R Das, Y Chen, J Liang, A Cao… - Cancer Research, 2013 - AACR
Background: Head and neck squamous cell carcinoma (HNSCC) is the fifth most common
cancer worldwide, with more than 40,000 new cases developing annually in the US alone …
cancer worldwide, with more than 40,000 new cases developing annually in the US alone …
Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16‐positive oropharynx cancer
JD Smith, ML Ludwig, AD Bhangale, C Brummel… - Head & …, 2023 - Wiley Online Library
Background We sought to characterize early changes in CD8+ tumor‐infiltrating
lymphocytes and tumor transcriptomes after induction cetuximab in a cohort with p16 …
lymphocytes and tumor transcriptomes after induction cetuximab in a cohort with p16 …